Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sarmustine (SarCNU) 是一种具有抗癌活性的烷化剂,通过 p53 依赖性和 p53 非依赖性途径抑制前列腺癌细胞的生长。Sarmustine 在体外介导 P140K 甲基鸟嘌呤-DNA-甲基转移酶转导的人 CD34(+)细胞的选择。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 3,250 | 现货 | ||
10 mg | ¥ 4,750 | 现货 | ||
25 mg | ¥ 7,480 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,600 | 现货 |
产品描述 | Sarmustine (SarCNU) is an alkylating agent with anticancer activity that inhibits the growth of prostate cancer cells via p53-dependent and p53-independent pathways.Sarmustine mediates the selection of P140K methylguanine-DNA-methyltransferase-transduced human CD34(+) cells in vitro. |
体内活性 | Sarmustine (SarCNU) (s.c.) implanted SF-295 and U-251 central nervous system (CNS) tumor xenografts. When given i.v., q4d for 3 doses, to athymic mice bearing s.c. SF-295 tumors, SarCNU, at an optimum of 167 mg/kg/dose, produced 9 tumor-free animals of 10 total animals, 1 regression, and no evidence of overt toxicity (> or =20% body weight loss). Furthermore, SarCNU retained high antitumor activity at two lower dose levels, 66 and 45% of the optimal dose, whereas BCNU demonstrated a progressive loss of antitumor activity at lower doses. Following p.o. administration, SarCNU similarly demonstrated antitumor activity. In the U-251 CNS tumor model, SarCNU yielded six of six tumor-free animals at 80 mg/kg/dose with i.p. administration q.d. for 5 days, starting on day 14, whereas BCNU, at 9 mg/kg/dose, yielded three of six tumor-free mice and one drug-related death. Again, SarCNU resulted in tumor-free animals at 66 and 45% of its optimal dose and was relatively nontoxic. Results of testing to date indicate that SarCNU is clearly more effective than BCNU against the human CNS tumors SF-295 and U-251 in vivo. These results encourage the initiation of clinical trials for SarCNU, in an effort to improve therapeutic approaches to glioma.[3] |
别名 | NSC-364432, SarCNU, Sarcosinamide, NSC 364432, NSC364432 |
分子量 | 222.63 |
分子式 | C6H11ClN4O3 |
CAS No. | 81965-43-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (224.59 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.4918 mL | 22.4588 mL | 44.9176 mL | 112.2939 mL |
5 mM | 0.8984 mL | 4.4918 mL | 8.9835 mL | 22.4588 mL | |
10 mM | 0.4492 mL | 2.2459 mL | 4.4918 mL | 11.2294 mL | |
20 mM | 0.2246 mL | 1.1229 mL | 2.2459 mL | 5.6147 mL | |
50 mM | 0.0898 mL | 0.4492 mL | 0.8984 mL | 2.2459 mL | |
100 mM | 0.0449 mL | 0.2246 mL | 0.4492 mL | 1.1229 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sarmustine 81965-43-7 NSC-364432 SarCNU Sarcosinamide NSC 364432 NSC364432 Inhibitor inhibitor inhibit